Navigation Links
Hatchtech Completes Treatment Phase of 2b Clinical Trial of New-Generation Head Lice Treatment Deovo™
Date:8/31/2011

MELBOURNE, Australia, Aug. 31, 2011 /PRNewswire-Asia/ -- Pharmaceutical company Hatchtech Pty Ltd has completed treatment of subjects for its Phase 2b clinical study to confirm the efficacy of its novel head lice treatment DeOvo™.

This Phase 2b trial is evaluating the efficacy, safety and tolerability of two dose levels of a single application of DeOvo™ compared to vehicle. The trial consists of treating 132 healthy subjects with head lice infestation, 2 years of age and older, in two study centers in the United States.

Hatchtech's proprietary product DeOvo™ is a topical formulation of a known metalloprotease inhibitor which targets proteases that are key to biological processes involved in insect hatch and survival.

Hatchtech Chairman Dr Paul Kelly commented: "We continue to be encouraged by Hatchtech's progress with its next generation head lice product DeOvo™ in line with our business objectives. The recruitment and treatment of subjects in this study has been achieved and we look forward to receiving results of the study later this year as planned."

"In the US it is estimated that 6-12 million people, mainly children aged 3-12 years, are infested each year with head lice (Pediculus humanus capitis). With the emergence of drug resistant lice and often poor efficacy of existing products, this under-served market represents a substantial commercial opportunity." Company Contact

Media InquiriesDr Paul Kelly

Dr Vern BowlesChairman

Chief Scientific Officer+61 (2) 8205-7379

+61 (0) 400 673 938pkelly@one-ventures.com

vbowles@hatchtech.com.auAbout the TrialThe following information is provided in accord with the AusBiotech/ASX Code of Best Practice for Reporting by Life Sciences Companies.Name of TrialHa02-003Blinding StatusDouble-blindPlacebo ControlledRandomized, vehicle-controlledDesignParallel treatment groupRouteTopicalFrequencySingle application Dose Levels0.37% w/v or 0.74% w/vNumber of Subjects132Subject Selection Criteria

  • 2 years of age or older
  • Good health
  • Has an active head lice infestation as determined by an experienced evaluator

  • Primary End Points

  • Proportion of all subjects who are lice free at all follow-up visits through the Day 14 visit

  • Secondary End Points

  • Safety and tolerability of Ha44 Gel
  • Proportion of index subjects who are lice free at all follow-up visits through the Day 14 visit
  • Proportion of all subjects who are lice free at each follow-up study visit (Day 1, 7, 14)
  • To evaluate the pharmacokinetics of Ha44 Gel in a subset of children 2-12 years of age and adults ≥ 18 years of age

  • Trial Location2 sites in USAExpected Duration of the TrialThe trial is expected to in completed in 9 monthsCommercial PartnersNoneSponsorHatchtech Pty LtdAbout HatchtechHatchtech Pty Ltd is a venture-backed specialty pharmaceutical product company that is developing technology for the control of invertebrate pests. The company's investors include, GBS Venture Partners, Queensland Biotechnology Fund, Uniseed, University of Melbourne Endowment Trust, Westscheme and OneVentures Innovation Fund. The OneVentures Innovation Fund is supported by the Australian Government through the IIF program. The IIF is an Australian Government venture capital initiative that has supported Hatchtech

    The company's lead product is DeOvo™, a class leading head lice control agent that aims to overcome the frustrating, costly and inconvenient cycles of re-treatment experienced currently by children and their parents.

    Hatchtech Pty Ltd
    Level 9, 278 Collins Street, Melbourne, 3000, Australia
    www.hatchtech.com.au

    About DeOvo™Despite its prevalence and high cost to the community, there have been few major advances in controlling head lice infestation in recent years. Most pediculicide products have little ovicidal activity and require two treatments (approximately 7 days apart), with the second application designed to treat those lice which have hatched from eggs that survive the first treatment. Non-compliance with this regimen and the difficulty in choosing the optimal time for the second application, are major difficulties in using these products. Hatchtech's DeOvo™, a topical formulation of a known metalloprotease inhibitor, has shown both ovicidal and lousicidal activity and offers the potential for a more effective treatment following a single application.

    About PediculosisIt is estimated that 6-12 million people, in the United States, mainly children aged 3-12, are infested each year with head lice (Pediculus humanus capitis). The direct cost of treatment is estimated at several hundreds of millions of dollars. Added to this direct economic burden are the indirect costs including missed days from school, lost work productivity by parents who stay home to treat their children and costs borne by the school itself in trying to control or prevent this problem. The total costs have been estimated to be 1billion USD in the US alone.


    '/>"/>

    SOURCE Hatchtech Pty Ltd
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
    2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
    3. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
    4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
    5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
    6. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
    7. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
    8. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
    9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
    10. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
    11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/4/2016)... Research and Markets has ... Myeloma Market and Competitive Landscape Highlights - ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ... Highlights 2016, provides comprehensive insights into Multiple ... Myeloma market valuations and forecast, Multiple Myeloma ...
    (Date:5/3/2016)... PUNE, India , May 4, 2016 /PRNewswire/ ... report spreads across 154 pages, profiling 09 key ... It is a professional and in-depth study on ... providing a basic overview of the industry including ... Insulin Needles market analysis is provided for the ...
    (Date:5/3/2016)... Pa. , May 3, 2016 ACME ... Jack Whelan and Delaware County ... (naloxone HCI) Nasal Spray in all ACME ... U.S. Centers for Disease Control and Prevention (CDC), naloxone has saved ... when police officers in Delaware County were ...
    Breaking Medicine Technology:
    (Date:5/4/2016)... ... May 04, 2016 , ... Qualitative ... seeks to add a deeper understanding of the program, policy or intervention being ... answers different yet important questions. , In a new brief released today, Reading ...
    (Date:5/4/2016)... SCOTTSDALE, AZ (PRWEB) , ... May 04, 2016 ... ... 2016 Annual Technology & Business Conference. The conference opened on Tuesday with Frank ... panel discussion on NCPDP’s PDMP Solution provided a deep dive on NCPDP’s model ...
    (Date:5/4/2016)... ... May 04, 2016 , ... The RIDER Institute announces ... of DRACO broad-spectrum antiviral therapeutics. DRACOs have proven effective against all 18 viruses ... 2016 at http://igg.me/at/EndTheVirus and runs for 60 days, we are raising ...
    (Date:5/4/2016)... ... May 04, 2016 , ... a2z, Inc. is ... and Canadian Association for Enterostomal Therapy (CAET) will be utilizing powerful and innovative ... to attendees and exhibitors for the 2016 WOCN Society & CAET Joint Conference—which ...
    (Date:5/4/2016)... ... ... May kicked off with Melanoma Monday , a multi-agency effort to raise ... encouraging her patients, as well as residents all around Dallas, Cleburne, Irving, and Plano, ... in the future. , The dermatology-specific awareness month ends with “Don’t Fry Day,” established ...
    Breaking Medicine News(10 mins):